Sai Parenterals Limited — Investor Meet, 18-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sai Parenterals Limited held an earnings conference call to discuss Q1 FY '27 performance. Management noted that year-on-year comparisons are not like-for-like due to Noumed Pharmaceuticals' consolidation. Total consolidated revenue was ₹182 Cr, with EBITDA at ₹27 Cr and PAT at ₹8 Cr. Gross margin improved to 41.8% sequentially. The company plans to redeploy ₹101.85 Cr from IPO funds for majority stakes in two pharmaceutical assets: Saicriti Pharma and Prathyak Laboratories, subject to shareholder approval. The Australian facility construction is on schedule, targeting physical completion by January 2027. Sai Parenterals reiterated its FY '27 revenue guidance of ₹750 Cr with an EBITDA margin of around 17%, expecting FY '28 to show performance improvement from these builds.